Commentary

Video

Dr Li on the Rationale of the MoonRISe-1 Trial in NMIBC

Author(s):

Roger Li, MD
Conference|American Urological Association Annual Meeting

Roger Li, MD, discusses the rationale of the phase 3 MoonRISe-1 trial (NCT06319820).

Roger Li, MD, a genitourinary oncologist at Moffitt Cancer Center, discusses the rationale of the phase 3 MoonRISe-1 trial (NCT06319820) examining TAR-210 vs intravesical chemotherapy in patients with non–muscle-invasive bladder cancer.

Related Videos
Peter Forsyth, MD
Paolo Caimi, MD
Janaki Neela Sharma, MD, University of Miami
Richard Kim, MD, Moffitt Cancer Center
Janaki Neela Sharma, MD, discusses CheckMate 901, and where nivolumab plus chemotherapy fits into the advanced urothelial cancer treatment paradigm.
Jennifer Scalici, MD
Steven H. Lin, MD, PhD
Anna Weiss, MD, associate professor, Department of Surgery, Oncology, associate professor, Cancer Center, University of Rochester Medicine
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Victor Moreno, MD, PhD
Related Content
Urothelial Cancer
November 16th 2024

Navigating a “Sea Change” in Frontline Urothelial Carcinoma Treatment

Oncology Unplugged
August 7th 2024

Park and Grivas Expand on Treatment Updates in Bladder Cancer

CAR T Cells in R/R Non-Hodgkin Lymphoma | Image Credit: © Tatiana Shepleva - stock.adobe.com
November 14th 2024

Transposon-Based BAFF CAR T Cells Show Early Efficacy, Safety in R/R Non-Hodgkin Lymphoma

Oncology Unplugged
July 24th 2024

Park and Sonpavde on Sacituzumab Govitecan Plus Enfortumab Vedotin in Metastatic Urothelial Cancer

Jennifer Amengual, MD, Herbert Irving Assistant Professor of Medicine, Division of Hematology and Oncology, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center
November 13th 2024

Real-World Experience With CAR T Varies From Trials in DLBCL

LASZLO – stock.adobe.com
November 13th 2024

BTK Inhibitors, CAR T-Cell Therapy Drive Paradigm Changes in Follicular Lymphoma